Li Gan
From Wikipedia, the free encyclopedia
- Yale School of Medicine (PhD)
- Peking University (BS)
Li Gan | |
|---|---|
| Education |
|
| Known for | Pathogenic tau acetylation; Microglia in neurodegeneration |
| Scientific career | |
| Fields | Neuroscience |
| Institutions | Weill Cornell Medical College |
| Doctoral advisor | Leonard K. Kaczmarek |
| Other academic advisors |
|
| Website | labs |
Li Gan is a neuroscientist and professor at Weill Cornell Medical College. She is known for her discovery of pathogenic tau protein acetylation in tauopathies and mechanisms of microglia dysfunction in neurodegeneration.[1]
Gan attended Peking University from 1986 to 1990[2] and earned a BS in Physiology.[3] She then attended Yale School of Medicine,[3] where she was advised by Leonard K. Kaczmarek and studied voltage-gated potassium channels in high frequency-firing neurons.[4] Gan received her PhD in Cellular & Molecular Physiology in 1996.[2] Gan conducted postdoctoral studies with Gerald Fischbach at Harvard Medical School and with Lennart Mucke at the Gladstone Institute of Neurological Disease. From 2000 to 2003, she worked at AGY Therapeutics Inc., a biotechnology company based in South San Francisco, CA.[2]
In 2003, Gan joined the Gladstone Institute as a staff research investigator and became an assistant adjunct professor in neurology at the University of California, San Francisco. She was promoted to assistant investigator/assistant professor in residence in 2009, and associate investigator/associate professor in 2011. Gan was promoted to full professor in 2016 and served as associate director of the Gladstone Institute of Neurological Disease from 2017 to 2018[5] before moving to Weill Cornell Medical College in 2018.[2]
As of 2018, Gan is the Burton P. and Judith B. Resnick Distinguished Professor in Neurodegenerative Disease. She leads the Helen and Robert Appel Alzheimer's Disease Research Institute, where she succeeded Gregory Petsko as director.[1]
